CN113712966A - 一种化合物在预防和治疗动物肿瘤中的应用 - Google Patents
一种化合物在预防和治疗动物肿瘤中的应用 Download PDFInfo
- Publication number
- CN113712966A CN113712966A CN202010456817.5A CN202010456817A CN113712966A CN 113712966 A CN113712966 A CN 113712966A CN 202010456817 A CN202010456817 A CN 202010456817A CN 113712966 A CN113712966 A CN 113712966A
- Authority
- CN
- China
- Prior art keywords
- cancer
- tumor
- animal
- compound
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 69
- 241001465754 Metazoa Species 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 title claims abstract description 54
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 25
- -1 stereoisomer Chemical class 0.000 claims description 17
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 241000699670 Mus sp. Species 0.000 claims description 13
- 229940002612 prodrug Drugs 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 201000009030 Carcinoma Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 238000010171 animal model Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 5
- 241000282836 Camelus dromedarius Species 0.000 claims description 4
- 241000283074 Equus asinus Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000772415 Neovison vison Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000024348 heart neoplasm Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000011061 large intestine cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 208000037959 spinal tumor Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 241000282485 Vulpes vulpes Species 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000010225 mixed cell type cancer Diseases 0.000 claims 1
- 208000029638 mixed neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 12
- 210000000822 natural killer cell Anatomy 0.000 abstract description 10
- 230000004614 tumor growth Effects 0.000 abstract description 7
- 230000002147 killing effect Effects 0.000 abstract description 6
- 230000008595 infiltration Effects 0.000 abstract description 5
- 238000001764 infiltration Methods 0.000 abstract description 5
- BJNWUKRWOQERPQ-UHFFFAOYSA-N 4-[3-[[2-amino-5-[2-(1-methylpiperidin-4-yl)-1,3-thiazol-5-yl]pyridin-3-yl]oxymethyl]phenyl]-2-methylbut-3-yn-2-ol Chemical compound C(C1=CC(C#CC(C)(O)C)=CC=C1)OC1=C(N=CC(C=2SC(C3CCN(CC3)C)=NC=2)=C1)N BJNWUKRWOQERPQ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000287531 Psittacidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000003741 urothelium Anatomy 0.000 description 2
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007369 Malignant Mixed Tumor Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- KTPVJUAWAAXVEZ-UHFFFAOYSA-N NC1=C(OCC2=CC(=CC=C2)C#CC2(O)CC2)C=C(C=N1)C1=CN(N=C1)C1CCOCC1 Chemical compound NC1=C(OCC2=CC(=CC=C2)C#CC2(O)CC2)C=C(C=N1)C1=CN(N=C1)C1CCOCC1 KTPVJUAWAAXVEZ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPRMFUAMSRXGDE-UHFFFAOYSA-N ac1o530g Chemical compound NCCN.NCCN DPRMFUAMSRXGDE-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Description
技术领域
本发明涉及化学医药技术领域,具体涉及一种化合物(4-(3-{2-氨基-5-[2-(1-甲基-哌啶-4-基)-噻唑-5-基]-吡啶-3-基氧基甲基}-苯基)-2-甲基丁-3-炔-2-醇)在预防和/或治疗动物肿瘤中的应用。
背景技术
随着我国经济发展,人们可基本满足温饱需求,精神方面的需求日益提高,且人口老龄化进入快速提升阶段,宠物产业快速发展,宠物数量剧增,目前国内宠物数量已上亿只,且养宠比例仍有较大上升空间,对宠物服务(特别是宠物医疗)的需求日益增加。
据统计,肿瘤已经成为兽医临床上动物危害最为严重的疾病之一,特别是宠物动物的肿瘤疾病,如发现不及时,治疗不理想,往往不仅给动物主人带来经济损失,还给动物主人带来巨大的精神损伤。动物肿瘤不但类型众多、发病部位广泛,生物学特性也各异,在临床表现出的症状也是五花八门,全身组织器官几乎都可以出现肿瘤病症。肿瘤疾病在动物疾病中占的比例过大,但在疾病的诊断和治疗过程中存在很多误区,针对动物肿瘤的治疗药物较少,导致肿瘤疾病的发现不及时,治疗效果不理想,进而影响宠物健康,甚至是生命安全。
目前现有技术中关于动物肿瘤疾病的治疗药物报道非常少,而需求很大。
发明内容
为克服现有技术的不足,本发明提供一种化合物:4-(3-{2-氨基-5-[2-(1-甲基-哌啶-4-基)-噻唑-5-基]-吡啶-3-基氧基甲基}-苯基)-2-甲基丁-3-炔-2-醇(其具有如下式Ⅰ的结构)或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物在制备预防和/或治疗动物肿瘤的药物中的应用
在本发明中,除非另外指出,否则本文中所述的“动物”为非人类动物,特别是脊椎动物,具体如哺乳动物(例如猪、牛、羊、马、驴、狗、猫、兔、鼠、狐、貉、貂、骆驼)、鱼类、鸟类(例如鸡、鸭、鹅、鸽子、鹌鹑、鹦鹉等)、两栖类动物、爬行类动物,特别是哺乳动物。特别是,本发明上述动物为家养动物,即由人类饲养驯化,且可以人为控制其繁殖的动物,用于例如食用、劳役、毛皮、宠物、实验等功能,例如经济动物、宠物、实验动物等。
在本发明的一个实施方式中,在上述应用中,动物为经济动物,如猪、牛、羊、马、驴、狐、貉、貂、骆驼等。
在本发明的一个实施方式中,在上述应用中,动物为宠物,如狗、猫、兔、鼠(如豚鼠、仓鼠、沙鼠、龙猫、松鼠等)等,特别是狗和猫。
在本发明的一个实施方式中,在上述应用中,动物为实验动物,如猴、狗、兔、鼠(如大鼠、小鼠、豚鼠等)等。
在本发明的一个实施方式中,上述肿瘤为恶性肿瘤,其中,恶性肿瘤的实例包括,但不限于,恶性上皮肿瘤、肉瘤、白血病、混合型肿瘤等。
具体地,上述恶性上皮肿瘤可以选自:肺癌(包括小细胞肺癌和非小细胞肺癌)、乳腺癌、肝癌、胰腺癌、结直肠癌、胃癌、胃食管腺癌、食管癌、小肠癌、大肠癌、贲门癌、子宫内膜癌、卵巢癌、输卵管癌、外阴癌、睾丸癌、前列腺癌、阴茎癌、肾癌、膀胱癌、肛门癌、胆囊癌、胆管癌、皮肤癌、鼻咽癌、喉癌、甲状腺癌、舌癌、颅脑肿瘤、心脏肿瘤、脊椎肿瘤等。
在本发明的一个实施例中,肿瘤为乳腺癌。
在本发明另一个实施例中,肿瘤为结肠癌。
具体地,上述药物还可以包含药学上可接受的辅料,特别是兽医领域可接受的辅料。
在本发明的一个实施方式中,上述药物中,式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物为唯一的活性成分。
在本发明的另一个实施方案中,上述药物中,式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物与一种或多种其它用于治疗肿瘤的活性成分联用,其中,式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物与该活性成分可配制用于同时、单独或顺序给药(simultaneous,separate orsequential administration)。
上述其它用于治疗肿瘤的活性成分可为现有技术中任何已知抗肿瘤活性成分,如抗肿瘤烷化剂、抗肿瘤抗代谢药、抗肿瘤抗生素、抗肿瘤植物药、抗肿瘤铂络合物、抗肿瘤抗体、抗肿瘤激素等。
具体地,上述药物的制剂形式可以是任何可药用的剂型,如,口服或胃肠外制剂,例如片剂(包括糖衣片剂、膜包衣片剂、舌下片剂、口腔崩解片、口腔片剂等等)、丸剂、粉剂、颗粒剂、胶囊剂(包括软胶囊、微胶囊)、锭剂、糖浆剂、液体、乳剂、混悬剂、控制释放制剂(例如,瞬时释放制剂、缓释制剂、缓释微囊)、气雾剂、膜剂(例如,口服崩解膜剂、口腔粘膜-粘附膜剂)、注射剂(例如,皮下注射、静脉注射、肌内注射、腹膜内注射)、静脉滴注剂,透皮吸收制剂、洗剂、粘附制剂、栓剂(例如,直肠栓剂、阴道栓剂)、鼻制剂、肺制剂(吸入剂)、眼睛滴剂等等。
具体地,上述药物通过口服、喷雾吸入、直肠用药、鼻腔用药、颊部用药、局部用药、非肠道给药,例如,皮下、静脉、肌内、鞘内、心室内、胸骨内、颅内或腹膜内注射或输入的途径向体内施加药物,或借助外植储器用药。
具体地,本发明上述药学上可接受的盐包括酸加成盐和碱加成盐。
具体地,上述酸加成盐包括但不限于来自无机酸诸如盐酸、硝酸、磷酸、硫酸、氢溴酸、氢碘酸和膦酸的盐,以及来自有机酸如脂肪族单羧酸和二羧酸、苯基取代的链烷酸、羟基链烷酸、链烷二酸、芳香酸和脂肪族和芳香族磺酸的盐。因此,这些盐包括但不限于硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、硝酸盐、磷酸盐、磷酸一氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、盐酸盐、氢溴酸盐、碘酸盐、乙酸盐、丙酸盐、辛酸盐、异丁酸盐、乙二酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、癸二酸盐、富马酸盐、马来酸盐、苦杏仁酸盐、苯甲酸盐、氯代苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、酞酸盐、苯磺酸盐、甲苯磺酸盐、苯基乙酸盐、柠檬酸盐、乳酸盐、马来酸盐、酒石酸盐和甲磺酸盐,还包含氨基酸的盐例如精氨酸盐、葡糖酸盐、半乳糖醛酸盐等。上述酸加成盐可以通过以常规方式使游离碱形式与足够量的所需酸接触形成盐的方式制备。可通过使盐形式与碱接触重新生成游离碱形式,并且以常规方式分离该游离碱。
具体地,上述碱加成盐与金属或者胺形成,诸如碱金属和碱土金属的氢氧化物,或者与有机胺形成。用作阳离子的金属的例子包括但不限于钠、钾、镁、和钙。适当的胺的例子包括但不限于N,N′-二苄基乙二胺、氯普鲁卡因、胆碱、二乙醇胺、乙二胺(乙烷-1,2-二胺)、N-甲基葡糖胺和普鲁卡因。碱加成盐可通过以常规方式使游离酸形式与足够量的所需碱接触形成盐的方式制备。可通过使盐形式与酸接触重新生成游离酸形式,并且以常规方式分离游离酸。
具体地,本发明上述立体异构体包括对映体、非对映体和几何异构体的形式存在。本发明的一些化合物具有环烷基,其可在超过一个碳原子上被取代,在这种情况下,其所有的几何形式,包括顺式和反式,及其混合物,都处在本发明的范围内。
具体地,本发明上述溶剂化物是指本发明的化合物与一种或多种溶剂分子的物理结合。该物理结合包括各种程度的离子和共价键合,包括氢键合。在某些情况下,溶剂化物可被分离出来,例如当一个或多个溶剂分子掺入到结晶固体的晶格中。“溶剂化物”包括溶液相的和可分离的溶剂化物。代表性的溶剂化物包括乙醇化物、甲醇化物等。“水合物”是其中一个或多个溶剂分子为H2O的溶剂化物。
具体地,本发明上述前药指适于对患者给药的无过分毒性、刺激性和变态反应等的并且对其应用目的有效的式Ⅰ化合物形式,包括缩醛、酯和两性离子形式。前药在体内转化(例如通过在血液中水解)得到上式的母体化合物。
本发明还提供一种治疗动物肿瘤的方法,其包括向由此需要的受试者给与治疗有效量的式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物或本发明上述药物的步骤。
具体地,上述给与治疗有效量的式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物或本发明上述药物的步骤可单独进行,也可与其他治疗手段(如手术、放疗、化疗等)联合应用。
具体地,上述方法中,动物和肿瘤具有本发明上述定义。
具体地,上述式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物或本发明上述药物的治疗有效量取决于诸多因素,包括受试者的年龄、体重、性别、自然健康状况、营养状况、服用时间、代谢速率、病症的严重程度以及诊治医师的主观判断,等。
本发明发明人通过实验发现,式Ⅰ的化合物可提高NK细胞的杀伤能力,提高动物肿瘤内部NK细胞的浸润,有效抑制肿瘤生长,改善动物生存情况,延长动物生存期,其可用于治疗动物肿瘤(例如乳腺癌、结肠癌),在兽用抗肿瘤药物领域可具有较佳的商业价值和应用前景。
附图说明
图1所示为4T-1小鼠模型的肿瘤体积检测结果。
图2所示为4T-1小鼠模型的肿瘤体积和存活率检测结果。
图3所示为相同剂量的活性化合物与对照化合物对小鼠肿瘤体积的影响实验结果。
图4所示为活性化合物对肿瘤组织的浸润性淋巴细胞的影响实验结果。
图5所示为NK体外杀伤实验结果。
图6所示为CT-26小鼠模型的肿瘤体积和存活率检测结果。
图7所示为小鼠体内NK细胞活化实验结果。
具体实施方式
除非另有定义,本发明中所使用的所有科学和技术术语具有与本发明涉及技术领域的技术人员通常理解的相同的含义。
在本发明中,除非另外指出,否则本文中所述的“动物”为非人类动物,特别是脊椎动物,具体如哺乳动物(例如猪、牛、羊、马、驴、狗、猫、兔、鼠、狐、貉、貂、骆驼)、鱼类、鸟类(例如鸡、鸭、鹅、鸽子、鹌鹑、鹦鹉等)、两栖类动物、爬行类动物。特别是,本发明上述动物为家养动物,即由人类饲养驯化,且可以人为控制其繁殖的动物,用于例如食用、劳役、毛皮、宠物、实验等功能,例如经济动物、宠物、实验动物等。其中,“经济动物”是指为肉用、乳用、皮毛、役用或其他经济目的而饲养的动物,如家畜、家禽等,“家畜”是指由人类饲养使之繁殖而利用,有利于农业生产的畜类;“家禽”是指人工豢养的鸟类动物,主要为了获取其肉、卵和羽毛,也有作为其他用处;“宠物”是指出于精神目的(例如玩赏和伴侣目的)而非经济目的而饲养的动物;“实验动物”是指为科学应用目的而饲养的动物。
本发明中,术语“肿瘤(tumor)”是指机体在各种致瘤因子作用下,局部组织细胞增生所形成的新生物(neogrowth),其分为良性肿瘤和恶性肿瘤两大类,其中,恶性肿瘤可包括癌和肉瘤,癌是指来源于上皮组织的恶性肿瘤,也称为恶性上皮肿瘤,其常见类型包括:鳞状细胞癌(常发生在身体原有鳞状上皮覆盖的部位,如皮肤、口腔粘膜、舌、喉头、食管、尿道、膀胱、子宫颈、阴道等处)、基底细胞癌、移形上皮癌(多发生与膀胱或尿道与肾盂等处的移形上皮)、腺上皮癌(包括腺癌(较多见于胃肠、胆囊、子宫体等)、粘液癌(常见于胃肠)、实性癌(多发生于乳腺,少数可发生于胃及甲状腺等));肉瘤是指间叶组织(包括纤维结缔组织、脂肪、肌肉、脉管、骨和软骨组织等)发生的恶性肿瘤;白血病是血液系统的恶性肿瘤。
术语“有效量”是指可在受试者中实现治疗、预防、减轻和/或缓解本发明所述疾病或病症的剂量。
术语“受试者”可以指接受本发明的方法以治疗、预防、减轻和/或缓解本发明所述疾病或病症的动物。
术语“治疗”包括在疾病或病症发作之后,根除、移除、逆转、缓解、改变或控制该疾病或病症。
术语“预防”指在疾病或病症发作之前,通过治疗以避免、最小化或令该疾病或病症难于发作或发展的能力。
下面将结合本发明实施例,对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
本实施例中所施用的活性化合物为4-(3-{2-氨基-5-[2-(1-甲基-哌啶-4-基)-噻唑-5-基]-吡啶-3-基氧基甲基}-苯基)-2-甲基丁-3-炔-2-醇,其具有如下结构:
对照化合物为1-(2-(3-((2-氨基-5-(1-(四氢-2H-吡喃-4-基)-1H-吡唑-4-基)吡啶-3-基氧基)甲基)苯基)乙炔基)环丙醇,其具有如下结构:
上述活性化合物I和对照化合物II的制备方法参见WO2019206049A1。
1、活性化合物对4T-1小鼠模型的作用
步骤如下:
(1)用含有10%FBS 1640培养4T-1细胞系;
(2)PBS收集细胞,台盼蓝染色,血球技术板计数,细胞浓度为1×107/ml;
(3)每只小鼠左下腹部靠乳腺处皮下注射100μl细胞悬液;
(4)用游标卡尺测量小鼠肿瘤体积大小,待小鼠肿瘤体积在100mm3左右时,分组;
(5)每组分别口服灌胃给药,剂量如图1和2所示。
用游标卡尺测量移植瘤体的长径(L)、短径(W)1次,取每例各小鼠肿瘤长短径平均值,按公式V=1/2(L×W2)计算移植瘤平均体积,并绘制肿瘤生长变化曲线。肿瘤体积大于2500mm3认为死亡,检测小鼠存活率。
小鼠肿瘤体积和存活率的检测结果分别如图1和2所示,图3所示为相同剂量(10mg/kg)的活性化合物与对照化合物对小鼠肿瘤体积的影响,其均表明该活性化合物可有效抑制4T-1肿瘤的生长,延长小鼠的生存期。
2、活性化合物对小鼠浸润淋巴细胞的影响
给药21天后,分离小鼠肿瘤组织的浸润性淋巴细胞(TIL),进行流式分析。
小鼠浸润淋巴细胞的分离步骤如下:
(1)用手术刀片将肿瘤组织切碎;
(2)加入胶原酶和DNAase消化15min;
(3)消化后的肿瘤在100μm的滤网上研磨并过滤至离心管中;
(4)1500rpm,4℃离心5min;
(5)全血及组织稀释液洗涤一次;
(6)用5ml稀释液重悬细胞沉淀;
(7)移液管吸取5ml的淋巴细胞分离液于15ml离心管中,小心吸取单细胞悬液沿壁缓慢加入至分离液上;
(8)900g,离心30min,加速减速brake设置为0;
(9)拿出离心管,小心吸取第二层乳白色淋巴细胞放在另外一个干净的离心管中;
(10)向离心管中加入10ml细胞洗涤液;
(11)250g,离心10min;
(12)弃去上清,用PBS缓冲液洗涤一次,重复步骤(11)离心;
(13)弃上清,底部沉淀即为肿瘤浸润的淋巴细胞。
所施用的活性化合物对肿瘤组织的浸润性淋巴细胞的影响实验结果如图4所示。结果表明,化合物可以降低表达PD-1、Tim-3和LAG-3的CD4 T细胞比例,增加表达CD107a的CD8 T细胞比例,从而说明该化合物可以挽救衰竭T细胞,增强T细胞杀伤作用。
3、NK体外杀伤实验
通过浓度200nM的活性化合物以及DMSO分别处理NK-92细胞24小时后,不同效靶比与K562孵育4小时,通过CytoTox 96Non-RadioactiveCytotoxicity Assay(货号G1780)490nm检测吸光度值。检测步骤如下:
(1)准备好细胞状态良好的效应细胞以及靶细胞;
(2)细胞计数后按照一定的比例将细胞加入到U型96孔板中,设置5个复孔;
(3)37℃孵育4h,提前45min加入溶液体积1/10的细胞裂解液;
(4)2000rpm,离心10min;
(6)每个孔加入50μL终止液,结束反应,使用酶标仪在490nm波长处检测吸光值,按照说明书公式计算细胞杀伤效率。
实验结果如图5所示,其表明所施用的活性化合物提高了NK-92细胞的体外杀伤能力。
4、活性化合物对CT-26小鼠模型的作用
实验步骤如下:
(1)使用含有10%FBS的DMEM培养CT-26细胞至对数期;
(2)用PBS缓冲液洗涤细胞一次;台盼蓝染色,血球技术板计数,调整细胞浓度为2×106个/ml;
(3)每只BALB/c小鼠皮下注射CT-26结肠癌细胞100μl,一共注射30只,在相同的条件下饲养;
(4)每3天观察小鼠的肿瘤生长情况;
(5)约7天后用游标卡尺测量肿瘤体积大小约为100mm3,此时对小鼠进行随机分为2组;
(6)每组分别灌胃施用活性化合物和对照,剂量为10mg/kg体重/天。
用游标卡尺测量移植瘤体的长径(L)、短径(W)1次,取每例各小鼠肿瘤长短径平均值,按公式V=1/2(L×W2)计算移植瘤平均体积,并绘制肿瘤生长变化曲线。肿瘤体积大于2500mm3认为死亡,检测小鼠存活率。
肿瘤体积和存活率的检测结果分别如图6A和6B所示,其表明活性化合物可抑制CT-26小鼠肿瘤生长,延长CT-26小鼠肿瘤生存期。
5、小鼠体内NK细胞活化
小鼠体内病毒感染时,会引起NK细胞的激活,Poly(I:C)注射类似病毒感染。同时向每只WT和HPK1-/-小鼠腹腔注射200ug Poly(I:C),18h后NK细胞活化,利用磁珠分选出NK细胞用于后续功能实验。
活性化合物灌胃组肿瘤体积为300mm3左右时,分离肿瘤组织的浸润性淋巴细胞(TIL),进行流式分析。
结果如图7所示,在蒸馏水对照组中,NK细胞肿瘤内浸润占比为21%,而经过活性化合物灌胃的小鼠肿瘤内浸润性的NK细胞占比提高至40%左右,表明活性化合物提高了肿瘤内部NK细胞的浸润。
6、统计分析
以上实验结果统计分析使用的软件为GraphPad Prism 7.0。RNAseq利用R语言分析展示,肿瘤的生长速度分析采用的是two-way ANOVA,肿瘤的生存曲线分析使用的是Log-rank(Mantel-Cox)test,其他实验统计分析均采用的是student’s t检验。每次实验至少经过3次的独立生物学重复。统计学差异*代表p<0.05,**代表p<0.01,***代表p<0.001,****代表p<0.0001。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换等,均应包含在本发明的保护范围之内。
本发明中描述的前述实施例和方法可以基于本领域技术人员的能力、经验和偏好而有所不同。
本发明中仅按一定顺序列出方法的步骤并不构成对方法步骤顺序的任何限制。
Claims (10)
2.如权利要求1所述的应用,其特征在于,所述动物为哺乳动物。
3.如权利要求2所述的应用,其特征在于,所述动物为家养动物。
4.如权利要求3所述的应用,其特征在于,所述动物为经济动物、宠物或实验动物;
优选地,所述经济动物选自:猪、牛、羊、马、驴、狐、貉、貂、骆驼;
优选地,所述宠物选自:狗、猫、兔、鼠;
优选地,所述实验动物选自:猴、狗、兔、鼠。
5.如权利要求1所述的应用,其特征在于,所述肿瘤为恶性肿瘤;
优选地,所述恶性肿瘤选自:恶性上皮肿瘤、肉瘤、白血病、混合型肿瘤。
6.如权利要求5所述的应用,其特征在于,所述恶性上皮肿瘤选自:肺癌、乳腺癌、肝癌、胰腺癌、结直肠癌、胃癌、胃食管腺癌、食管癌、小肠癌、大肠癌、贲门癌、子宫内膜癌、卵巢癌、输卵管癌、外阴癌、睾丸癌、前列腺癌、阴茎癌、肾癌、膀胱癌、肛门癌、胆囊癌、胆管癌、皮肤癌、鼻咽癌、喉癌、甲状腺癌、舌癌、颅脑肿瘤、心脏肿瘤、脊椎肿瘤。
7.如权利要求1所述的应用,其特征在于,所述肿瘤为乳腺癌或结肠癌。
8.如权利要求1-7任一项所述的应用,其特征在于,所述药物还包含药学上可接受的辅料。
9.如权利要求1-7任一项所述的应用,其特征在于,所述药物中,所述式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物为唯一的活性成分;或,
所述式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物或氘代化合物与一种或多种其它用于治疗肿瘤的活性成分联用。
10.如权利要求1-7任一项所述的应用,其特征在于,所述药物为口服制剂或肠道外制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010456817.5A CN113712966A (zh) | 2020-05-26 | 2020-05-26 | 一种化合物在预防和治疗动物肿瘤中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010456817.5A CN113712966A (zh) | 2020-05-26 | 2020-05-26 | 一种化合物在预防和治疗动物肿瘤中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113712966A true CN113712966A (zh) | 2021-11-30 |
Family
ID=78672028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010456817.5A Pending CN113712966A (zh) | 2020-05-26 | 2020-05-26 | 一种化合物在预防和治疗动物肿瘤中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113712966A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110396087A (zh) * | 2018-04-25 | 2019-11-01 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
-
2020
- 2020-05-26 CN CN202010456817.5A patent/CN113712966A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110396087A (zh) * | 2018-04-25 | 2019-11-01 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
CN110396088A (zh) * | 2018-04-25 | 2019-11-01 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jepson | Exotic animal medicine: a quick reference guide | |
WO2021254118A1 (zh) | Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用 | |
CN101589026A (zh) | 治疗脑神经胶质瘤的方法 | |
EP1397105B1 (en) | Compositions for inhibiting angiogenesis | |
US4332814A (en) | Treatment of diarrhoea | |
CN102065865A (zh) | 多发性骨髓瘤治疗 | |
Hu et al. | Growth and cardiovascular development are repressed by florfenicol exposure in early chicken embryos | |
JP6908287B2 (ja) | 脳腫瘍の処置のための治療剤としての2−アミノピリミジン誘導体 | |
US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
JP7442662B2 (ja) | 動物の病原体感染症の予防及び/又は治療における化合物の使用 | |
CN113712966A (zh) | 一种化合物在预防和治疗动物肿瘤中的应用 | |
JP2018501294A (ja) | タウリンのコロナウイルス属及び/又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び/又は治療における応用 | |
D’Agostino | Insectivores (insectivora, macroscelidea, scandentia) | |
EP1776956B1 (en) | Preventive and/or therapeutic agent for calcipenia | |
Kubiak | Corn Snakes | |
US20040048808A1 (en) | Methods for inhibiting angiogenesis | |
CN106554385B (zh) | 多肽类化合物及其在畜禽方面的应用 | |
RU2709535C1 (ru) | Способ профилактики и лечения паразитарных болезней сельскохозяйственных животных и птиц | |
RU2549496C1 (ru) | Гомеопатическое лекарственное средство, оказывающее стресспротективное и ростостимулирующее действие, регулирующее обмен веществ у молодняка сельскохозяйственных животных и птицы | |
CN111671756A (zh) | TGF-βSmad信号通路抑制剂作为制备治疗肝囊型包虫病药物的应用 | |
WO2021012138A1 (zh) | 二氨基胍衍生物及其饲用组合物在制备兽医用药物中的应用 | |
CN110721174B (zh) | 一种用于防治鱼类粘孢子虫病的药物 | |
RU2527329C2 (ru) | Способ получения комплексного иммунометаболического препарата с антиинфекционной активностью | |
WO2022143984A1 (zh) | 一种用于治疗癌症的药物组合物及其制备方法和用途 | |
CN102358730A (zh) | 一种小分子mek蛋白激酶抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211130 |
|
RJ01 | Rejection of invention patent application after publication |